Filter by: Subject

Filter by: Subject

Results Per Page:

Human immunodeficiency virus (HIV) (5)
Tuberculosis (TB) (5)
Nucleic acid amplification testing (NAAT) (4)
Africa (2)
Multidrug-resistant tuberculosis (MDR-TB) (2)
Mycobacterium tuberculosis (MTB) (2)
South Africa (SA) (2)
Acquired immune deficiency syndrome (AIDS) (1)
Acute HIV infection (AHI) (1)
Antenatal care (ANC) (1)
Antenatal clinics (1)
Aspen Ceftriaxone (AC) (1)
Awareness (1)
Behandlung (1)
Bio-marker discovery (1)
Biochemistry (1)
Black person (1)
Blood (1)
Cardiovascular magnetic resonance (CMR) (1)
Circumcision (1)
CMV viral load (VL) (1)
Colistin methanesulfonate (1)
Colistin sulfate (1)
Community-acquired bacterial meningitis (CABM) (1)
Community-acquired infections -- South Africa (1)
Complex relationships (1)
Computed tomography (CT) (1)
Condom use (1)
Coronavirus disease 2019 (COVID-19) (1)
COVID-19 pandemic (1)
Cross-resistance (1)
Cytomegalovirus (CMV) (1)
Electron microscopy (1)
Extensively drug-resistant tuberculosis (XDR-TB) (1)
FDG-PET (1)
Field performance (1)
Fludeoxyglucose (FDG) (1)
G878A mutation (1)
Gas chromatographic time-of-flight mass spectrometric (GC × GC-TOFMS) (1)
Gas chromatography (1)
Gas emissions (1)
Health behavior (1)
Health status (1)
Healthcare (1)
High risk population (1)
Highly active antiretroviral therapy (HAART) (1)
HIV counseling and testing (HCT) (1)
HIV/AIDS (1)
Human skin volatiles (1)
Immunocompromised individuals (1)
Immunosuppressed patients (1)
Impact of treatment (1)
Infection (1)
Infection prevention (1)
Infection risk (1)
INSTI HIV‐1/‐2 antibody test (INSTI test) (1)
Ketones (1)
Left ventricular end diastolic mass (LVEDM) (1)
Lipodystrophy (1)
Mass spectrometry (1)
Meningitis -- Treatment -- South Africa (1)
Microbiome (1)
Mosquito semiochemicals (1)
Mother-to-child transmission (MTCT) (1)
Mycolic acids (1)
Nanodrug delivery (1)
Non-invasive passive sampling (1)
Passive sampling (1)
Patient management (1)
Patienten management (1)
Patients (1)
Phagosomes (1)
Pharmacokinetics of Aspen Ceftriaxone (1)
Point-of-care (POC) (1)
Polydimethylsiloxane (PDMS) (1)
Polymyxin (1)
Population research (1)
Positron emission tomography (PET) (1)
Pregnancy (1)
Pulmonary (1)
Rapid HIV‐1/‐2 testing (1)
Risk (1)
Risk reduction (1)
Rocephin (1)
Rocephin (ROC) (1)
rrs Gene (1)
Second-line injectable drugs (SLIDs) (1)
Selfpromoted uptake (1)
Semiochemicals (1)
Sexual behavior (1)
Silicones (1)
Skin microbiome (1)
Targeting (1)
TB (1)
Testing (1)
Therapy (1)
Transmission (1)
Treatment (1)
Tshwane District, South Africa (1)
Tuberculosis -- Treatment (1)